Drug Profile
Tirasemtiv - Cytokinetics
Alternative Names: CK-2017357; CK-357Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Cytokinetics
- Class 2 ring heterocyclic compounds; Alkynes; Imidazolidines; Pyrazines; Small molecules
- Mechanism of Action Troponin tropomyosin complex stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Amyotrophic lateral sclerosis; Muscle fatigue; Myasthenia gravis; Spinal muscular atrophy
Most Recent Events
- 01 Nov 2018 Cytokinetics completes the phase III extension VIGOR-ALS trial for Amyotrophic lateral sclerosis in USA, Canada, Belgium, Germany, France, Ireland, Netherlands, Spain, United Kingdom, Italy and Portugal (PO) (NCT02936635)
- 08 Dec 2017 Efficacy and adverse events data from the phase III VITALITY-ALS trial in Amyotrophic lateral sclerosis released by Cytokinetics
- 21 Nov 2017 Suspended - Phase-II for Muscle fatigue in USA (PO)